Search - tctmd.com

Displaying 21 - 40 of 414

Sort: Relevancy | Date

News Conference News TCT 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

Caitlin E. Cox

October 28, 2024

Presentation TCT 2024

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

Presenter: Angelo Oliva

October 27, 2024

News Conference News ESC 2024

AI Tool Fails to Boost Outcomes in ED Triage of Suspected CV Conditions

Caitlin E. Cox

September 12, 2024

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

Todd Neale

September 01, 2024

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA

Caitlin E. Cox

June 25, 2024

News Daily News

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Yael L. Maxwell

June 20, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Daily News

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

Yael L. Maxwell

March 21, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2024

Shelley Wood

February 01, 2024

News Daily News

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Yael L. Maxwell

January 10, 2024

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

News Daily News

Guiding DAPT Based on Genes or Platelet Tests Still ‘Tempting’

Yael L. Maxwell

November 08, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2023

Shelley Wood

November 01, 2023

Presentation TCT 2023

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

Presenter: Hyunki LEE

October 25, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Presentation TCT 2023

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

Presenter: Seong Huan Choi

October 25, 2023

Presentation TCT 2023

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

Presenter: Ji-Yeon Kim

October 25, 2023

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Advertisement

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

AI Tool Fails to Boost Outcomes in ED Triage of Suspected CV Conditions

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

TCTMD’s Top 10 Most Popular Stories for January 2024

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Guiding DAPT Based on Genes or Platelet Tests Still ‘Tempting’

TCTMD’s Top 10 Most Popular Stories for October 2023

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content